据了解，行动方案明确提出，到2030年，实现健康体重管理支持性环境广泛建立，专业服务体系逐步健 全，居民健康体重管理意识和技能显著提升，健康生活方式更加普及，超重肥胖率上升趋势得到明显减 缓，重点人群体重异常状况得以改善。 具体而言，行动方案提到要打造健康主题公园、健康步道、健康单位、健康社区、健康家庭、健康食 堂、健康餐厅、健康小屋等支持环境，建设"金角银边"运动健身场所，配套建设智慧化健身器材和体质 监测站点，提升健身设施覆盖率。鼓励家庭、医疗卫生机构、学校、机关企事业单位、宾馆酒店等配置 体重秤。 引导研发推广低盐低脂低糖川菜 体重管理纳入健康四川行动 本报讯 （成都日报锦观新闻记者 胡瑰玮） 近年来，超重肥胖问题日益凸显，据监测，四川儿童青少年 超重、肥胖率分别为13.37%、8.73%，18岁及以上居民超重率、肥胖率分别为36.02%、15.39%，因超重 肥胖等危险因素导致的心脑血管疾病、糖尿病和部分癌症等慢性病已成为威胁居民健康的重大公共卫生 问题。 为进一步健全健康体重管理服务体系，提升全民健康体重管理意识和能力。记者从四川省卫生健康委获 悉，日前，省爱卫会组织制定了《健康体重管理专项行动方案 ...

2025年的中国医美市场，在喧嚣中迎来了一个微妙的分水岭。 《每日经济新闻》记者查阅上述消费榜单发现，曾经的"抗衰明星"——超声炮"失速"，玻尿酸则在价格 战的泥潭中稳守"顶流"地位。 对此，有业内分析指出，在合规壁垒趋严与技术迭代提速的背景下，医美市场加速重塑，行业"马太效 应"正在以一种近乎残酷的方式上演，而与此同时，减重与脱发治疗赛道，正成为资本竞逐的一个"新大 陆"。 再生填充材料继续"狂飙" 近日，医美平台美呗发布的"2025年医美平台消费榜单"显示，再生填充材料成为"年度MVP"，2025年销 售额同比增长93.40%，成为连续3年狂飙的"热门选手"。 在整个再生填充材料赛道狂飙的同时，各个品牌2025年销售额的增速却出现分化："臻爱塑菲"以463% 的增长速度排名第一；艾维岚同比增长78.71%，展现出稳扎稳打的特点；"伊妍仕"的市场受到挤压，同 比下降56%。 公开资料显示，"臻爱塑菲"为爱美客旗下产品。 《每日经济新闻》记者了解到，2025年，"臻爱塑菲"销售额增速虽然强劲，但其对爱美客的业绩贡献还 有待验证。财报数据显示，2025年前三季度，爱美客营收和归母净利润均出现超过20%的同比下降 ...

Core Viewpoint - The article emphasizes the importance of healthy eating during the Spring Festival, highlighting the need to balance festive indulgence with health considerations to avoid gastrointestinal issues and other health risks. Group 1: Health Risks of Common Snacks - Many popular holiday snacks, such as flavored sunflower seeds and dried fruits, contain high levels of salt and sugar, which can exceed recommended daily limits [3][5] - For instance, 100g of flavored sunflower seeds can contain 2 to 3 grams of salt, while 50g of preserved plums may have 15 to 20 grams of sugar [3][5] - The Chinese dietary guidelines recommend that daily sugar intake should not exceed 25 grams and salt intake should not exceed 5 grams [3] Group 2: Dietary Recommendations - It is advised to consume salty and oily foods in moderation, as they can lead to health issues such as hypertension and increased cardiovascular risks [5][7] - A balanced approach to meals is recommended, starting with vegetables, followed by protein sources like shrimp and fish, and limiting fatty meats and fried foods [7] - Monitoring weight and maintaining a healthy lifestyle through exercise is crucial during the holiday season [7] Group 3: Gastrointestinal Health Concerns - Gastrointestinal diseases are more prevalent during the Spring Festival, often due to foodborne illnesses or overeating [8] - Individuals with pre-existing conditions such as gallstones or high cholesterol should be particularly cautious to avoid acute pancreatitis and cholecystitis [8] - The article stresses the importance of enjoying the holiday while maintaining a focus on healthy eating habits to enhance overall well-being [8]

（来源：新华日报） 省人大代表、省疾病预防控制中心病原微生物研究所BSL-3实验室副主任 郭喜玲 省政协委员、镇江市第一人民医院院长 蒋鹏程 主持人 樊玉立 □ 本报记者 樊玉立 2月4日，省人大代表、省人大常委会委员、省疾病预防控制中心病原微生物研究所BSL-3实验室副主任 郭喜玲和省政协委员、镇江市第一人民医院院长蒋鹏程走进新华报业传媒集团2026江苏省两会"今天我 主持"演播室，共话如何积极落实"体重管理"三年行动，助力百姓科学减重，健康生活。 主持人：统计数据显示，目前我国青少年肥胖率上升较快；此外，由于工作压力、久坐等，很多职场人 也被体重问题所困扰。各级部门应当如何建立针对这两个群体的体重干预模式？ 郭喜玲：目前，江苏卫健系统针对青少年超重和肥胖做了以下工作：强化部门协作，将体重管理、膳食 营养和身体活动知识等融入中小学常规教育；提升基层服务能力；完善干预体系；推动家庭社会支持性 环境建设；持续推进智能化适宜技术应用；持续推进体重管理门诊设置；加强监测评估，借助专业力量 定期组织开展儿童青少年体质健康监测。 针对职场群体的体重管理，我建议优化办公环境与设施，比如设立站立式办公区。将体重管理融入工作 ...

中新网北京2月6日电(记者 赵方园)近日，北京大学新闻与传播学院等机构发布的《中国大众体重管理及 营养认知调查报告》显示，91.7%的大众认可体重管理的重要性，但38.8%的群体存在认知偏差，且行 为转换障碍突出。 《报告》显示，营养认知方面则呈现出显著的"城乡知识鸿沟"和年龄差异——城镇居民明显高于农村居 民(但农村居民的代餐了解使用显著超越城镇居民)、40—44岁年龄段显著高于其他年龄段。这些发现精 准揭示了当前大众体重管理和营养认知的核心困境，为后续政策实施、行业发展和公众行动提供了重要 参考依据。 值得关注的是，人工智能(AI)已成为体重管理的新兴工具，超过半数(53.6%)受访者已开始使用。然而， 用户对其存在六大核心痛点，包括担忧错误建议、功能复杂、缺乏情感支持、成本过高、可能削弱自主 能力以及数据安全风险。 针对体重管理与临床健康的密切关联，北京协和医院临床营养科主任医师陈伟指出，超重肥胖引发的代 谢性疾病、心血管疾病等健康风险日益凸显，科学体重管理具有极强的必要性与紧迫性。他同时指 出，"减重5-15%能显著改善甚至缓解多种肥胖相关代谢性疾病。" 如何通过优化膳食结构实现健康体重？中国农业大学 ...

Group 1: Market Overview - The global sales of GLP-1 drugs have surpassed Merck's Keytruda, with Eli Lilly's Tirzepatide generating $36.5 billion and Novo Nordisk's Semaglutide achieving $36.1 billion in 2025 [1] - The sales of Tirzepatide's weight loss indication increased by 175% year-on-year, while the diabetes indication grew by 99% [1] - The potential patient market for weight loss is significantly large, indicating a strong demand for GLP-1 drugs [1] Group 2: Company Developments - Several domestic companies, including Innovent Biologics, Jiangsu Hengrui Medicine, Tonghua Dongbao, and East China Pharmaceutical, are actively developing GLP-1 drugs to meet weight loss market demands [2] - Innovent Biologics' GLP-1 weight loss drug, Sema, has been approved for sale in China, contributing to the company's revenue growth, which is expected to exceed 10 billion yuan in 2025 [3] - Hengrui Medicine is developing HRS9531, which shows promising results in weight loss and blood sugar control, while also improving cardiovascular and renal risk factors [4] Group 3: Competitive Strategies - Companies are adopting differentiated strategies in drug development, such as creating oral formulations, extending drug half-lives, and innovating sales models [5] - Hengrui Medicine is focusing on developing a GLP-1/GIP dual receptor agonist, which aims to enhance efficacy and safety [5] - Tonghua Dongbao is also working on a GLP-1/GIP dual receptor agonist, with clinical trials progressing smoothly [5] Group 4: Research and Development Focus - Innovent Biologics is expanding its research pipeline to include long-acting, oral, and multi-target projects, aiming to provide more effective treatment options [6] - East China Pharmaceutical is developing an oral small molecule GLP-1 drug, with successful completion of all subject enrollments for its clinical phase III study in weight management [6]

体重超标，已成为国人面临的重大健康问题之一。我国18岁及以上居民超重及肥胖率已突破50%。 国家卫健委会同多部门启动的 "体重管理年"活动正加速落地，以期通过服务创新、科技赋能等手段， 提高全民体重管理意识和技能。 肠道菌群与体重密切相关，益生菌可通过多种作用机制影响体重，代谢效率决定能量利用与体重变 化。 澳洲专业益生菌品牌lifespace益倍适，依托10余年微生态科研积累与自主知识产权菌株库并基于多 项国家级和PCT国际级专利助力国民体重管理活动，已实现了多株自主研发菌株的商业化应用。 近日，lifespace益倍适携手会议合作伙伴Nature Custom Media在杭州举办"生命科学全球先锋论坛" (以下简称"论坛")，Nature Portfolio社群互动主管兼自然大师课堂首席讲师Jeffrey Robens登台分享了前 沿行业视角。他指出，微生物组对代谢健康与衰老的影响日益成为研究热点，其相关成果在高质量期刊 中发表趋势显著上升;特定益生菌与微生物代谢物可通过调节免疫、改善肠道环境等机制支持体重管理 与代谢健康。 本次论坛还汇聚了国际益生菌和益生元科学协会(ISAPP)创始人Professo ...

Group 1 - The core viewpoint of the article suggests that individuals who prefer wheat-based foods have a higher risk of cardiovascular diseases compared to those who prefer rice, with a risk increase of 40.8% [1] - Regular consumption of wheat products is associated with a higher likelihood of obesity due to several factors, including the type of protein present in wheat and rice, the caloric content of cooked foods, and dietary structure [2][3][4] Group 2 - The article emphasizes that moderation is key, recommending a daily intake of wheat products to be around 150 grams, and suggests alternating with other grains [7] - It advises against consuming only refined wheat products and encourages the inclusion of whole grain and vegetable-based noodles for better nutritional benefits [8] - Cooking methods should be mindful of oil and salt usage, as fried or mixed dishes often contain higher amounts of these, which can negatively impact health [9] - Nutritional balance is important, and it is recommended to pair wheat-based foods with vegetables and proteins to ensure a well-rounded diet and reduce caloric intake [10]

Summary of Key Points from the Conference Call Industry Overview - The conference focused on the pharmaceutical industry, particularly the advancements in drug development and the impact of AI technology on research and development processes across major multinational corporations (MNCs) [1][3][6]. Core Insights and Arguments 1. **AI in Drug Development**: Major pharmaceutical companies like JSK, AstraZeneca, BMS, Pfizer, Eli Lilly, and Novartis are leveraging AI to enhance R&D efficiency and reduce costs. For instance, JSK has made significant progress in molecular prediction design and disease modeling using AI [1][3]. 2. **Impact of U.S. Policies**: Policies from the Trump administration, such as the Inflation Reduction Act (IRI) and Most Favored Nation (MFN) treatment, have had a limited impact on global sales for pharmaceutical companies. Many firms are confident that increasing innovation funding can offset price declines in the U.S. market [1][7]. 3. **Weight Management Products**: Companies like Novo Nordisk and Eli Lilly are facing pricing challenges with their weight management products, which are limiting patient access. However, they believe that over time, more patients will be able to afford these treatments, thus expanding market share [1][7]. 4. **Cancer Research Initiatives**: Pfizer plans to initiate multiple analysis studies targeting various cancers and is focusing on the ADC field related to integrin V6. Collaborations are also noted, such as AbbVie with Rongchang Biotech and BMS with OncoOne [1][9]. 5. **Investment in Cardiovascular and Metabolic Areas**: AstraZeneca is investing heavily in cardiovascular, renal, and metabolic research, including the introduction of oral GLP-1 small molecules [1][10][11]. Additional Important Insights - **Chinese Pharmaceutical Companies**: Chinese firms are increasingly recognized for their innovation capabilities and are becoming integral to the strategies of major overseas pharmaceutical companies. The Chinese CRO industry is also gaining importance due to its scale and cost advantages [4][15][17]. - **Future Goals of AstraZeneca**: AstraZeneca aims to achieve $80 billion in revenue by 2030, with significant investments in cardiovascular and oncology sectors [11]. - **Pfizer's Market Strategy**: Pfizer is focusing on the weight management market and plans to disclose data on GLP-1 monthly dosing regimens, with expectations of the global weight management market reaching $150 billion by 2030 [12]. - **Clinical Research Developments**: Companies like Rongchang Biotech and DiZhe Pharma are advancing their clinical research, with multiple trials planned for new drug candidates [21][22]. This summary encapsulates the key points discussed during the conference, highlighting the ongoing trends and strategic directions within the pharmaceutical industry.

Group 1 - The report titled "China's Public Weight Management and Nutrition Cognition Survey Report" was released by Peking University, highlighting the current state of public awareness and practices regarding weight management in China [1] - 91.7% of the public recognizes the importance of weight management, but 38.8% exhibit cognitive biases and significant barriers to behavioral change [1] - There is a notable "urban-rural knowledge gap" and age differences in nutrition cognition, with urban residents showing higher awareness than rural residents, although rural residents have a better understanding of meal replacement products [1] Group 2 - Clinical risks associated with overweight and obesity, such as metabolic and cardiovascular diseases, underscore the urgent need for scientific weight management, as emphasized by a clinical nutrition expert [1] - A professor from China Agricultural University provided a systematic interpretation of the role of dietary structure in achieving healthy weight, offering a practical dietary plan for the public [2] - A roundtable discussion highlighted the need for a comprehensive support system to facilitate the transition from awareness to action in weight management, focusing on policy guidance, social promotion, and individual empowerment [2]